Omnicell vs Solventum
Omnicell (OMCL) and Solventum (SOLV) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $1.5B
- Last close
- $32.51
- 12 months
- −5.3%
- Market value
- $14.3B
- Last close
- $84.50
- 12 months
- +6.3%
At a glance
- The biggest part of Omnicell's revenue is Connected devices, software licenses, and other (48%); at Solventum it is Cost of product (76%).
- Omnicell earns 90% of its revenue in the United States, Solventum 56%.
- By market value, Solventum ($14.3B) is about 9.6 times Omnicell ($1.5B).
- Over the last 12 months Omnicell's share price moved −5.3% and Solventum's +6.3%; against the S&P 500 that is −11.0 points and +0.6 points.
- In their last fiscal years Omnicell kept 0.2% of revenue as net income and Solventum 18.7%.
- In the last 90 days insiders reported 0 open-market purchases at Omnicell and 0 at Solventum; members of Congress disclosed 0 trades in Omnicell and 0 in Solventum.
- Next results: Omnicell Feb 3, 2027, Solventum Feb 24, 2027.
How each one makes money: Omnicell revenue · Solventum revenue
Share prices on one chart
Omnicell and Solventum, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Omnicell OMCLNASDAQ · Health Care Technology | Solventum SOLVNYSE · Health Care Technology | |
|---|---|---|
| Size and profitability | ||
| Market value | $1.5B | $14.3B |
| Revenue, last fiscal year | $1.18B | $8.32B |
| Net income, last fiscal year | $2.05M | $1.56B |
| Net marginNet income as a share of revenue | 0.2% | 18.7% |
| Free cash flow | $86.9M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Solventum against
Common questions
How is Omnicell different from Solventum?
Omnicell (OMCL) is in Health Care Technology on NASDAQ, with $1.18B of revenue in its last fiscal year and a net margin of 0.2%. Solventum (SOLV) is in Health Care Technology on NYSE, with $8.32B of revenue in its last fiscal year and a net margin of 18.7%. The biggest part of Omnicell's revenue is Connected devices, software licenses, and other (48%); at Solventum it is Cost of product (76%). Omnicell earns 90% of its revenue in the United States, Solventum 56%. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Omnicell and Solventum compare in size?
Solventum has the larger market value: Omnicell $1.5B and Solventum $14.3B, at the last close.
Whose share price rose more over the last 12 months, OMCL or SOLV?
Over the last 12 months Omnicell moved −5.3% and Solventum +6.3%. Past price moves say nothing about the future.
Which has had more insider buying, Omnicell or Solventum?
Since 2006, Omnicell insiders reported 10 open-market purchases against 1 for Solventum. These are counts of what was filed, not a view on either stock.
Do members of Congress trade OMCL or SOLV?
In the last 12 months, members of Congress disclosed 0 trades in Omnicell (OMCL) and 3 in Solventum (SOLV).
When did insiders last buy OMCL and SOLV?
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Omnicell pageSolventum pageRare insider trades this weekAll comparisons
https://oqro.io/compare/omcl-vs-solv


